https://pharminent.com/neuromarket-pulse/neuromarket-pulse-weekly-neuroscience-competitive-intelligence-july-1-2026/ 2026-07-01T21:09:59Z Pharminent en NeuroMarket Pulse • Weekly Neuroscience Competitive Intelligence • July 1, 2026 2026-07-01T21:09:57Z Blog https://pharminent.com/fda-selects-seven-for-precheck-pilot-to-advance-drug-manufacturing/ 2026-07-01T17:54:21Z Pharminent en FDA Selects Seven for PreCheck Pilot to Advance Drug Manufacturing 2026-07-01T17:54:21Z Blog https://pharminent.com/ipsen-acquires-memo-therapeutics-for-up-to-e700m-in-second-deal-in-three-days/ 2026-07-01T17:53:24Z Pharminent en Ipsen Acquires Memo Therapeutics for Up to €700M in Second Deal in Three Days 2026-07-01T17:53:20Z Blog https://pharminent.com/manufacturing-intelligence/manufacturing-intelligence-weekly-digest-july-1-2026/ 2026-07-01T17:40:59Z Pharminent en Manufacturing Intelligence • Weekly Digest • July 1, 2026 2026-07-01T17:40:57Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-1-2026/ 2026-07-01T16:14:14Z Pharminent en Strategic News Watch • July 1, 2026 2026-07-01T16:14:12Z Blog https://pharminent.com/ipsen-to-buy-swiss-biotech-memo-therapeutics-in-potential-800m-deal/ 2026-07-01T21:27:01Z Pharminent en Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal 2026-07-01T13:51:27Z Blog https://pharminent.com/eli-lilly-and-regeneron-among-7-companies-picked-for-fda-precheck-pilot-program/ 2026-07-01T21:24:37Z Pharminent en Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program 2026-07-01T13:22:08Z Blog https://pharminent.com/ean-2026-real-world-data-supports-safety-and-efficacy-of-abbvies-vyalev-in-parkinsons/ 2026-07-01T18:02:13Z Pharminent en EAN 2026: Real-world data supports safety and efficacy of AbbVie's Vyalev in Parkinson's 2026-07-01T12:50:20Z Blog https://pharminent.com/sarepta-secures-early-2027-fda-decision-for-duchenne-drugs-pushing-past-confirmatory-fail/ 2026-07-01T21:24:47Z Pharminent en Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail 2026-07-01T11:56:42Z Blog https://pharminent.com/lillys-jaypirca-wins-chmp-opinion-for-cll-across-all-lines/ 2026-06-30T20:53:22Z Pharminent en Lilly's Jaypirca Wins CHMP Opinion for CLL Across All Lines 2026-06-30T20:53:22Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-june-30-2026/ 2026-06-30T20:30:33Z Pharminent en Oncology Intelligence Digest • June 30, 2026 2026-06-30T20:30:31Z Blog https://pharminent.com/nejm-retracts-pivotal-tavneos-paper-as-amgens-fda-data-integrity-fight-deepens/ 2026-06-30T19:41:11Z Pharminent en NEJM Retracts Pivotal Tavneos Paper as Amgen's FDA Data-Integrity Fight Deepens 2026-06-30T19:41:11Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-june-30-2026/ 2026-06-30T16:56:02Z Pharminent en Strategic News Watch • June 30, 2026 2026-06-30T16:56:00Z Blog https://pharminent.com/evommune-ends-development-of-lead-asset-in-chronic-hives-after-mid-stage-efficacy-woes/ 2026-06-30T15:08:29Z Pharminent en Evommune ends development of lead asset in chronic hives after mid-stage efficacy woes 2026-06-30T12:39:05Z Blog